-
To high-fat feed, we added the same amounts of various fatty acids to the following groups: high fat base group (HFD group), 2% caprylic acid feed (C8:0 group), 2% palmitic acid feed (C16:0 group) and 2% eicosapentaenoic acid feed (EPA group). The proportion of energy from fat in the HFD group was 37.11%, whereas that in the other groups was 39.68%. The feed, as previously described[13], was provided by Beijing Huafukang Company (license No.: SCXK Beijing 2014-0008).
-
The experimental animals included 56 male 6-week-old C57BL/6J mice, which were purchased from SPF (Beijing) biotechnology Co, Ltd. The mice were randomly divided into four groups according to body weight. High fat feed was provided for 1 week and then replaced by intervention feed. The experiment was completed at 12 weeks. During the experiment, fasting weight was measured once per month (drinking water was not limited during fasting the night before measurements). The mouse bedding and drinking water were replaced every 2–3 days, and the remaining amount and added amount of mouse feed were recorded. The daily average feed consumption of each mice was calculated. All experimental procedures were performed in strict accordance with the regulations of the Ethics Committee of the International Association for the Study of Pain (Zimmermann, 1983) and National Guidelines for the Care and Use of Laboratory Animals (The Ministry of Science and Technology of China, 2006). This research was approved by the Animal Care and Use Committee of the Chinese PLA General Hospital.
-
The RAW246.7 cell line was obtained from the American Type Culture Collection, and the cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (HyClone, Logan, UT, USA), 100 U/mL penicillin (Invitrogen), 0.1 mg/mL streptomycin (HyClone) and 1 mm sodium pyruvate at 37 ℃ under humidified air and 5% CO2. The cell count was adjusted to 4 × 105 – 8 × 105/mL (measured with a hemocytometer: cell number/mL = 100 cells per 100 cells/400 × 10,000 dilution factor), were harvested for subsequent assays.
-
Various fatty acids were diluted with 95% ethanol solution and serum-free medium (containing 20 mg/mL BSA); 200 mmol/L was added to culture wells, and 0.3 mmol/L with cAMP was added to culture wells.
Experimental groups and treatments: RAW 264.7 cells were seeded in 24-well plates at approximately 2 × 105 per well and randomly divided into five groups (n = 6): normal group, LPS group (final LPS concentration 50 ng/mL), LPS+C8:0 group (LPS final concentration 50 ng/mL and C8:0 final concentration 200 mmol/L), LPS+EPA group (LPS final concentration 50 ng/mL and EPA final concentration 200 mmol/L) and LPS+cAMP group (LPS final concentration 50 ng/mL and cAMP final concentration is 0.3 mmol/L). After 24 h, the cells were collected and isolated to extract RNA and proteins for analysis after being washed three times with refrigerated PBS.
-
The levels of serum lipid were determined using commercial kits. TC and triglycerides (TG) (Wako, Osaka, Japan), and HDL-C and LDL-C (Abcam, Cambridge, UK) were measured with commercial kits, and the ratio of HDL-C to LDL-C was subsequently calculated.
-
After the addition of fatty acids, the cells were continuously cultured for 24 h, and cell lysates were collected from each group. After 4 ℃, 3,000 r/min centrifugation for 10 min, the supernatant was collected. TNF-α, IL-1β, IL-6, interleukin-10 (IL-10) and MCP-1 were determined in cells and serum according to the manufacturer’s instructions for the ELISA kit (R&D Systems, Minneapolis, MN, USA).
-
Total RNA from RAW cells and aorta samples (approximately 50 mg) was isolated with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and then reverse transcribed with a reverse transcription system kit (NEB, M-MLV kit). The cycling conditions were 25 ℃ for 5 min, 50 ℃ for 15 min, 85 ℃ for 5 min and 4 ℃ for 10 min for cDNA, then 50 ℃ for 2 min, 95 ℃ for 10 min, 95 ℃ for 30 s and 60 ℃ for 30 s. After 40 cycles, dissolution curves were analyzed, and only the sample with a single dissolution peak was collected. With normalization to the β-actin gene, the relative expression levels were calculated with the △Ct method, and the experiments were repeated in triplicate. The primers used in the current study are listed in Table 1.
Table 1. RT-PCR primer list
Indicators Primer Sequence (5‘−3’) Size (bp) β-actin Forward GGCCGAGGAGCAAGAATGG 118 Reverse CATGCACTCTGCGATACGCT ACBA1 Forward GCTTGTTGGCCTCAGTTAAGG 135 Reverse GTAGCTCAGGCGTACAGAGAT JAK2 Forward AGTGGCGGCATGATTTTGTT 181 Reverse GCTCGAACGCACTTTGGTAA STAT3 Forward GTAGAGCCATACACCAAGCAGCAG 123 Reverse AATGTCGGGGTAGAGGTAGACAAGT p65 Forward CACCGGATTGAAGAGAAGCG 194 Reverse AAGTTGATGGTGCTGAGGGA Note. ABCA1, ATP-binding cassette transporter A1; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; p65, pNF-κBp65. -
The cells were extracted with RIPA buffer (CST). Immunoblotting for STAT3 (1:1,000), JAK2 (1:1,000), p-STAT3 (1:1,000), p-JAK2 (1:1,000), p65 (1:1,000), β-actin (1:1,000) and ABCA1 (1:200) was performed with established procedures. Bands were visualized with a chemiluminescence detection system (Vilber Lourmat, France) according to the manufacturer’s instructions.
-
On the basis of a preliminary experiment, G*Power 3.1.9.2 software (Heinrich-Heine University, Germany) was used to calculate the minimum sample size required for the detection of a significant difference (P < 0.05). All data in this report are presented as the mean ± standard derivation, and significance was defined as P < 0.05 (two-tailed). A one-way analysis of variance was performed for data analysis. The Tukey-Kramer multiple comparison was used to determine the statistical significance of differences among various groups. SPSS 26.0 (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses.
-
At 4, 8 and 12 weeks during the intervention, the fasting body weights in the C8:0 group and EPA group were found to be significantly lower than those in the HFD group and C16:0 group (P < 0.05) (Figure 1). During the study, no significant difference in average feed intake was observed (P > 0.05) (Figure 2).
Figure 1. Effects of different fatty acids (C8:0, C16:0 and EPA) on fasting body weight of C57BL/6J mice. C8:0, caprylic acid; C16:0, palmitic acid; EPA, eicosapentaenoic acid; HFD, high-fat diet. Data in the figure are expressed as the mean ± SD with 14 samples in each group (n = 14). aP < 0.05, versus high-fat group; bP < 0.05, versus C16:0 group; cP < 0.05, versus EPA group
-
After 12 weeks of intervention, half the mice (n = 7) were randomly selected from each group and intraperitoneally injected with LPS. The expression levels of lipid metabolism indexes, inflammatory factors and mRNA of ABCA1 and JAK2/STAT3, pathway related factors in arteries were measured.
At the end of the intervention, compared with that in the HFD group, the serum TC in the C8:0 group was significantly lower (P < 0.05). The levels of serum TC and LDL-C were significantly lower in the EPA group than the HFD group, whereas the LDL-C levels were significantly higher, and the HDL-C/LDL-C ratio was clearly higher, than that in the C16:0 group (P < 0.05) (Table 2). Our data showed that C8:0 decreased the level of TC. EPA decreased the TC and LDL-C, and up-regulated the HDL-C/LDL-C ratio (P > 0.05).
Table 2. Effects of different fatty acids on blood lipids in C57BL/6j mice without or with LPS injection (
$\bar x$ ± s, n = 7)Indicators −LPS +LPS C8:0 C16:0 EPA HFD C8:0 C16:0 EPA HFD TC (mmol/L) 3.27 ± 0.14a 3.49 ± 0.29 3.15 ± 0.38a 3.67 ± 0.16 3.47 ± 0.23a 3.95 ± 0.40 2.86 ± 0.48a,b 4.26 ± 0.80 TG (mmol/L) 0.67 ± 0.11 0.62 ± 0.21 0.71 ± 0.24 0.93 ± 0.35 0.71 ± 0.19 0.66 ± 0.11 0.63 ± 0.27 0.57 ± 0.09 HDL-C (mmol/L) 1.39 ± 0.13 1.19 ± 0.25 1.28 ± 0.16 1.40 ± 0.16 1.47 ± 0.13 1.44 ± 0.08 1.38 ± 0.18 1.29 ± 0.11 LDL-C (mmol/L) 0.56 ± 0.07c 0.55 ± 0.01c 0.45 ± 0.03a,b 0.55 ± 0.03c 0.44 ± 0.04a 0.52 ± 0.07 0.39 ± 0.07a,b 0.54 ± 0.08 HDL-C/LDL-C 2.52 ± 0.45 2.17 ± 0.46 2.82 ± 0.42b 2.55 ± 0.27 3.32 ± 0.25a 2.83 ± 0.44 3.69 ± 0.75a,b 2.45 ± 0.56 Note. C8:0, caprylic acid; C16:0, palmitic acid; EPA, eicosapentaenoic acid; HFD, high-fat diet; LPS, lipopolysaccharide; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; aP < 0.05, versus HFD group; bP < 0.05, versus C16:0 group; cP < 0.05, versus EPA group. At the end of the intervention, after injection of LPS, the serum TC and LDL-C levels were significantly lower, and the HDL-C/LDL-C ratio was clearly higher, in the C8:0 group than the HFD group (P < 0.05). Moreover, the serum TC and LDL-C levels were significantly lower, and the HDL-C/LDL-C ratio was clearly higher, in the EPA group than the C16:0 and HFD groups (P < 0.05) (Table 2). Our study indicated that both C8:0 and EPA decreased the TC and LDL-C levels and increased the HDL-C/LDL-C ratio after LPS treatment.
-
At the end of the intervention, the levels of IL-1β and TNF-α in the HFD group (+LPS) were significantly higher, and those of IL-10 were significantly lower, than those in the HFD group (-LPS) (P < 0.05). The levels of TNF-α and MCP-1 clearly increased in the C16:0 group (+LPS), thus indicating that LPS increased the serum inflammation in the mice (P < 0.05) (Table 3).
Table 3. Effects of different fatty acids on serum inflammatory factors in C57BL/6j mice (
$\bar x$ ± s, n = 7)Indicators −LPS +LPS C8:0 C16:0 EPA HFD C8:0 C16:0 EPA HFD IL-1β 4.89 ± 0.53 4.81 ± 1.37 4.67 ± 0.82 4.65 ± 0.48* 4.81 ± 0.91 5.33 ± 1.08 5.10 ± 0.68 5.43 ± 0.46 IL-6 110.78 ± 17.19 117.18 ± 24.29 114.56 ± 19.85 113.53 ± 15.99 119.89 ± 13.51 127.49 ± 30.40 119.46 ± 16.80 119.42 ± 22.97 IL-10 3.29 ± 1.09 2.42 ± 1.09 2.62 ± 0.60 2.57 ± 0.54* 4.85 ± 1.06a,b,c 2.50 ± 1.00 2.66 ± 0.90 1.89 ± 0.28 MCP-1 44.75 ± 10.54 51.93 ± 6.02* 44.08 ± 9.04 52.54 ± 6.04 48.51 ± 10.38b 61.65 ± 3.60 51.70 ± 4.97b 58.86 ± 6.47 TNF-α 4.00 ± 0.69 4.73 ± 0.92* 3.87 ± 0.97 4.78 ± 0.80* 4.05 ± 1.09a,b 6.23 ± 1.01 4.26 ± 0.70a,b 6.91 ± 0.86 Note. C8:0, caprylic acid; C16:0, palmitic acid; EPA, eicosapentaenoic acid; HFD, high-fat diet; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor α; IL-1β, interleukin-1β; IL-6, interleukin-6; IL-10, interleukin-10; MCP-1, monocyte chemoattractant protein-1; *P < 0.05, versus LPS group; aP < 0.05, versus HFD group; bP < 0.05, versus C16:0 group; cP < 0.05, versus EPA group. After intraperitoneal injection of LPS, the levels of MCP-1 in the C8:0 group were significantly lower than those in the C16:0 group, and the level of TNF-α was significantly lower than those in the HFD group and the C16:0 group (P < 0.05). Compared with those in the other three groups, the IL-10 levels in the C8:0 group were significantly higher, whereas the TNF-α levels in the EPA group were significantly lower than those in the HFD group and C16:0 group. In addition, the MCP-1 levels in the EPA group were significantly lower than those in the C16:0 group (P < 0.05). Our data suggested that C8:0 significantly inhibited LPS-stimulated serum inflammation in mice (Table 3).
-
By the end of the intervention, the mRNA levels of JAK2/STAT3 significantly increased; those of NF-κB and TNF-α dramatically decreased in each group after LPS injection; and those of ABCA1 also significantly increased in the C8:0 and EPA groups (P < 0.05) (Table 4). Compared with those in the other three groups, the expression levels of ABCA1 in the C8:0 group were significantly higher, whereas those of TNF-α and NF-κB in the C8:0 group and EPA group were significantly lower than those in the HFD group and C16:0 group. JAK2 in the C8:0 group was significantly higher than that in the C16:0 group, and STAT3 in the C8:0 group was significantly higher than that in the HFD group (P < 0.05).
Table 4. Effects of different fatty acids on the mRNA expression of ABCA1/JAK2/STAT3 pathway-related molecules in the aorta in C57BL/6j mice (
$\bar x$ ± s, n = 7)Indicators −LPS +LPS C8:0 C16:0 EPA HFD C8:0 C16:0 EPA HFD ABCA1 0.17 ± 0.04a,b,c,* 0.09 ± 0.02 0.11 ± 0.01* 0.09 ± 0.02 0.22 ± 0.02a,b,c 0.07 ± 0.03 0.14 ± 0.01b 0.10 ± 0.05 JAK2 0.21 ± 0.03b,* 0.14 ± 0.04* 0.18 ± 0.05 0.16 ± 0.04* 0.57 ± 0.23a,b,c 0.29 ± 0.15 0.17 ± 0.02 0.26 ± 0.10 STAT3 0.23 ± 0.05a,* 0.17 ± 0.06* 0.19 ± 0.03* 0.15 ± 0.03* 0.93 ± 0.30a,b,c 0.26 ± 0.05 0.34 ± 0.15 0.38 ± 0.16 TNF-α 0.08 ± 0.01a,b,* 0.15 ± 0.04* 0.08 ± 0.02a,b,* 0.17 ± 0.06* 0.15 ± 0.06a,b 0.27 ± 0.08 0.14 ± 0.06a,b 0.26 ± 0.07 NF-κB 0.08 ± 0.03a,b,* 0.13 ± 0.03* 0.09 ± 0.02a,b 0.15 ± 0.03* 0.12 ± 0.02a 0.18 ± 0.04 0.10 ± 0.04a 0.24 ± 0.08 Note. C8:0, caprylic acid; C16:0, palmitic acid; EPA, eicosapentaenoic acid; HFD, high-fat diet; LPS, lipopolysaccharide; ABCA1, ATP-binding cassette transporter A1; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; TNF-α, tumor necrosis factor α; NF-κB, nuclear factor kappa B; *P < 0.05, versus +LPS (comparison in the same group ±LPS); aP < 0.05, versus HFD group; bP < 0.05, versus C16:0 group;
cP < 0.05, versus EPA group.After intraperitoneal injection with LPS, the expression levels of ABCA1 and JAK2/STAT3 were significantly higher in the C8:0 group than the HFD, C16:0 and EPA groups, the mRNA levels of NF-κB, TNF-α were lower than those in the HFD group (P < 0.05), and the mRNA levels of TNF-α were also lower than those in the C16:0 group (P < 0.05). Meanwhile, compared with that in the C16:0 group, the expression of ABCA1 mRNA in the EPA group was significantly higher, and the expression of TNF-α mRNA was inhibited. Moreover, compared with that in the HFD group, the expression of NF-κB and TNF-α mRNA in the EPA group was inhibited (P < 0.05) (Table 4). Our data revealed that C8:0 up-regulated ABCA1 and resulted in downstream inhibition of the mRNA levels of NF-κB and TNF-α.
-
After LPS treatment, the levels of cytokines in RAW264.7 cells significantly increased, and consequently the levels of TNF-α, MCP-1, IL-6 and IL-1β were significantly higher than those in the normal group, whereas those of IL-10 were significantly lower (P < 0.05). The levels of TNF-α, MCP-1, IL-6 and IL-1β in the LPS+C8:0 group, LPS+EPA group and LPS+cAMP group were significantly lower than those in the LPS group, but the levels of IL-10 were higher (P < 0.05). The levels of TNF-α, IL-6 and MCP-1 were significantly lower in the LPS+C8:0 group and LPS+EPA group than the LPS+cAMP group (P < 0.05) (Figure 3). Compared with those in the LPS+EPA group, the levels of IL-1β were higher, and the levels of IL-6 were lower, in the LPS+C8:0 group. Our findings indicated that C8:0 inhibited the expression of inflammatory factors in RAW264.7 cells stimulated by LPS.
Figure 3. Effects of C8:0 and EPA on inflammatory factors of RAW264.7 cells stimulated by LPS. TNF-α, tumor necrosis factor α; IL-1β, interleukin-1β; IL-6, interleukin-6; IL-10, interleukin-10; MCP-1, monocyte chemoattractant protein-1; NC, normal contrast; LPS, lipopolysaccharide; C8:0; caprylic acid; EPA, eicosapentaenoic acid; cAMP, cyclic adenosine monophosphate. Data in the figure are expressed as the mean ± SD with 6 samples in each group (n = 6). *P < 0.05, versus NC group; aP < 0.05, versus LPS group; bP < 0.05, versus LPS+EPA group; cP < 0.05, versus LPS+cAMP group
-
Compared with that in the normal group, the expression level of ABCA1 mRNA in RAW264.7 cells treated with LPS was clearly lower, and the expression of JAK2, STAT3 and p65 mRNA was higher (P < 0.05). Moreover, the expression of ABCA1 mRNA in the LPS+C8:0 group was clearly higher than that in the LPS and LPS+EPA group and the expression of JAK2 and p65 mRNA was significantly lower than that in the LPS group (P < 0.05). Furthermore, the mRNA expression level of STAT3 in the LPS+C8:0 group was significantly higher than that in the LPS+EPA group (P < 0.05). However, the mRNA expression of ABCA1, JAK2, STAT3 and p65 in the LPS+C8:0 group was no different from that in the LPS+cAMP group (P > 0.05). Compared with that in the LPS+cAMP group, the mRNA expression of ABCA1 and STAT3 was lower, and the expression of p65 was higher, in the LPS+EPA group (Figure 4). Thus, C8:0 up-regulated the ABCA1 and STAT3 pathway in RAW264.7 cells stimulated by LPS and decreased the mRNA expression of p65.
Figure 4. Effects of C8:0 and EPA on JAK2/STAT3 mRNA expression in RAW264.7 cells stimulated by LPS. NC, normal contrast; LPS, lipopolysaccharide; C8:0, caprylic acid; EPA, eicosapentaenoic acid; cAMP, cyclic adenosine monophosphate; ABCA1, ATP-binding cassette transporter A1; JAK2, Janus Kinase 2; STAT3, signal transducer and activator of transcription 3; p65, pNF-κBP65. Data in the figure are expressed as the mean ± SD with 6 samples in each group (n = 6). *P < 0.05, versus NC group; aP < 0.05, versus LPS group; bP < 0.05, versus LPS+EPA group; cP < 0.05, versus LPS+cAMP group
-
Compared with that in the normal group, the expression of ABCA1, p-JAK2 and p-STAT3 protein was significantly lower after LPS treatment, whereas the expression of p65 protein was significantly higher (P < 0.05). Meanwhile, in the LPS+C8:0 group and LPS+EPA group, compared with the LPS group and LPS+cAMP group, the protein expression levels of ABCA1, p-JAK2 and p-STAT3 were significantly higher (P < 0.05). Compared with that in the LPS group, p65 protein expression was significantly lower in the LPS+C8:0 group and LPS+EPA group (P < 0.05). Therefore, C8:0 up-regulated ABCA1 and the p-JAK2/p-STAT3 pathway in RAW264.7 cells stimulated by LPS and decreased the expression of p65 inflammatory factor protein (Figure 5).
Figure 5. Effects of C8:0 and EPA on JAK2/STAT3 protein expression in RAW264.7 cells stimulated by LPS. NC, normal contrast; LPS, lipopolysaccharide; C8:0, caprylic acid; EPA, eicosapentaenoic acid; cAMP, cyclic adenosine monophosphate; ABCA1, ATP-binding cassette transporter A1; JAK2, Janus Kinase 2; STAT3, signal transducer and activator of transcription 3; p65, pNF-κBP65. Data in the figure are expressed as the mean ± SD with 4 samples in each group (n = 4). *P < 0.05, versus NC group; aP < 0.05, versus LPS group; bP < 0.05, versus LPS+EPA group; cP < 0.05, versus LPS+cAMP group
doi: 10.3967/bes2022.014
Caprylic Acid Improves Lipid Metabolism, Suppresses the Inflammatory Response and Activates the ABCA1/p-JAK2/p-STAT3 Signaling Pathway in C57BL/6J Mice and RAW264.7 Cells
-
Abstract:
Objective This study aimed to investigate the effects of caprylic acid (C8:0) on lipid metabolism and inflammation, and examine the mechanisms underlying these effects in mice and cells. Methods Fifty-six 6-week-old male C57BL/6J mice were randomly allocated to four groups fed a high-fat diet (HFD) without or with 2% C8:0, palmitic acid (C16:0) or eicosapentaenoic acid (EPA). RAW246.7 cells were randomly divided into five groups: normal, lipopolysaccharide (LPS), LPS+C8:0, LPS+EPA and LPS+cAMP. The serum lipid profiles, inflammatory biomolecules, and ABCA1 and JAK2/STAT3 mRNA and protein expression were measured. Results C8:0 decreased TC and LDL-C, and increased the HDL-C/LDL-C ratio after injection of LPS. Without LPS, it decreased TC in mice (P < 0.05). Moreover, C8:0 decreased the inflammatory response after LPS treatment in both mice and cells (P < 0.05). Mechanistic investigations in C57BL/6J mouse aortas after injection of LPS indicated that C8:0 resulted in higher ABCA1 and JAK2/STAT3 expression than that with HFD, C16:0 and EPA, and resulted in lower TNF-α, NF-κB mRNA expression than that with HFD (P < 0.05). In RAW 264.7 cells, C8:0 resulted in lower expression of pNF-κBP65 than that in the LPS group, and higher protein expression of ABCA1, p-JAK2 and p-STAT3 than that in the LPS and LPS+cAMP groups (P < 0.05). Conclusion Our studies demonstrated that C8:0 may play an important role in lipid metabolism and the inflammatory response, and the mechanism may be associated with ABCA1 and the p-JAK2/p-STAT3 signaling pathway. -
Key words:
- Caprylic acid /
- Inflammatory cytokine /
- ATP binding cassette transporter A1 /
- Janus kinase 2 /
- Signal transducer and activator of transcription 3
注释: -
Figure 1. Effects of different fatty acids (C8:0, C16:0 and EPA) on fasting body weight of C57BL/6J mice. C8:0, caprylic acid; C16:0, palmitic acid; EPA, eicosapentaenoic acid; HFD, high-fat diet. Data in the figure are expressed as the mean ± SD with 14 samples in each group (n = 14). aP < 0.05, versus high-fat group; bP < 0.05, versus C16:0 group; cP < 0.05, versus EPA group
Figure 3. Effects of C8:0 and EPA on inflammatory factors of RAW264.7 cells stimulated by LPS. TNF-α, tumor necrosis factor α; IL-1β, interleukin-1β; IL-6, interleukin-6; IL-10, interleukin-10; MCP-1, monocyte chemoattractant protein-1; NC, normal contrast; LPS, lipopolysaccharide; C8:0; caprylic acid; EPA, eicosapentaenoic acid; cAMP, cyclic adenosine monophosphate. Data in the figure are expressed as the mean ± SD with 6 samples in each group (n = 6). *P < 0.05, versus NC group; aP < 0.05, versus LPS group; bP < 0.05, versus LPS+EPA group; cP < 0.05, versus LPS+cAMP group
Figure 4. Effects of C8:0 and EPA on JAK2/STAT3 mRNA expression in RAW264.7 cells stimulated by LPS. NC, normal contrast; LPS, lipopolysaccharide; C8:0, caprylic acid; EPA, eicosapentaenoic acid; cAMP, cyclic adenosine monophosphate; ABCA1, ATP-binding cassette transporter A1; JAK2, Janus Kinase 2; STAT3, signal transducer and activator of transcription 3; p65, pNF-κBP65. Data in the figure are expressed as the mean ± SD with 6 samples in each group (n = 6). *P < 0.05, versus NC group; aP < 0.05, versus LPS group; bP < 0.05, versus LPS+EPA group; cP < 0.05, versus LPS+cAMP group
Figure 5. Effects of C8:0 and EPA on JAK2/STAT3 protein expression in RAW264.7 cells stimulated by LPS. NC, normal contrast; LPS, lipopolysaccharide; C8:0, caprylic acid; EPA, eicosapentaenoic acid; cAMP, cyclic adenosine monophosphate; ABCA1, ATP-binding cassette transporter A1; JAK2, Janus Kinase 2; STAT3, signal transducer and activator of transcription 3; p65, pNF-κBP65. Data in the figure are expressed as the mean ± SD with 4 samples in each group (n = 4). *P < 0.05, versus NC group; aP < 0.05, versus LPS group; bP < 0.05, versus LPS+EPA group; cP < 0.05, versus LPS+cAMP group
S1. The effect of caprylic acid on lipid metabolism and inflammatory response and its proposed mechanism. Arrows (↓) represent a decreasing level and downregulation of activity or protein or mRNA expression. Arrows (↑) represent an increasing level and upregulation of activity or protein or mRNA expression. ABCA1, ATP-binding cassette transporter A1; JAK2, Janus Kinase 2; STAT3, signal transducer and activator of transcription 3; NF-κB, nuclear factor kappa B; TNF-α, tumor necrosis factor α; IL-1β, interleukin-1β; IL-6, interleukin-6; IL-10, interleukin-10; MCP-1, monocyte chemoattractant protein-1; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol
Table 1. RT-PCR primer list
Indicators Primer Sequence (5‘−3’) Size (bp) β-actin Forward GGCCGAGGAGCAAGAATGG 118 Reverse CATGCACTCTGCGATACGCT ACBA1 Forward GCTTGTTGGCCTCAGTTAAGG 135 Reverse GTAGCTCAGGCGTACAGAGAT JAK2 Forward AGTGGCGGCATGATTTTGTT 181 Reverse GCTCGAACGCACTTTGGTAA STAT3 Forward GTAGAGCCATACACCAAGCAGCAG 123 Reverse AATGTCGGGGTAGAGGTAGACAAGT p65 Forward CACCGGATTGAAGAGAAGCG 194 Reverse AAGTTGATGGTGCTGAGGGA Note. ABCA1, ATP-binding cassette transporter A1; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; p65, pNF-κBp65. Table 2. Effects of different fatty acids on blood lipids in C57BL/6j mice without or with LPS injection (
$\bar x$ ± s, n = 7)Indicators −LPS +LPS C8:0 C16:0 EPA HFD C8:0 C16:0 EPA HFD TC (mmol/L) 3.27 ± 0.14a 3.49 ± 0.29 3.15 ± 0.38a 3.67 ± 0.16 3.47 ± 0.23a 3.95 ± 0.40 2.86 ± 0.48a,b 4.26 ± 0.80 TG (mmol/L) 0.67 ± 0.11 0.62 ± 0.21 0.71 ± 0.24 0.93 ± 0.35 0.71 ± 0.19 0.66 ± 0.11 0.63 ± 0.27 0.57 ± 0.09 HDL-C (mmol/L) 1.39 ± 0.13 1.19 ± 0.25 1.28 ± 0.16 1.40 ± 0.16 1.47 ± 0.13 1.44 ± 0.08 1.38 ± 0.18 1.29 ± 0.11 LDL-C (mmol/L) 0.56 ± 0.07c 0.55 ± 0.01c 0.45 ± 0.03a,b 0.55 ± 0.03c 0.44 ± 0.04a 0.52 ± 0.07 0.39 ± 0.07a,b 0.54 ± 0.08 HDL-C/LDL-C 2.52 ± 0.45 2.17 ± 0.46 2.82 ± 0.42b 2.55 ± 0.27 3.32 ± 0.25a 2.83 ± 0.44 3.69 ± 0.75a,b 2.45 ± 0.56 Note. C8:0, caprylic acid; C16:0, palmitic acid; EPA, eicosapentaenoic acid; HFD, high-fat diet; LPS, lipopolysaccharide; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; aP < 0.05, versus HFD group; bP < 0.05, versus C16:0 group; cP < 0.05, versus EPA group. Table 3. Effects of different fatty acids on serum inflammatory factors in C57BL/6j mice (
$\bar x$ ± s, n = 7)Indicators −LPS +LPS C8:0 C16:0 EPA HFD C8:0 C16:0 EPA HFD IL-1β 4.89 ± 0.53 4.81 ± 1.37 4.67 ± 0.82 4.65 ± 0.48* 4.81 ± 0.91 5.33 ± 1.08 5.10 ± 0.68 5.43 ± 0.46 IL-6 110.78 ± 17.19 117.18 ± 24.29 114.56 ± 19.85 113.53 ± 15.99 119.89 ± 13.51 127.49 ± 30.40 119.46 ± 16.80 119.42 ± 22.97 IL-10 3.29 ± 1.09 2.42 ± 1.09 2.62 ± 0.60 2.57 ± 0.54* 4.85 ± 1.06a,b,c 2.50 ± 1.00 2.66 ± 0.90 1.89 ± 0.28 MCP-1 44.75 ± 10.54 51.93 ± 6.02* 44.08 ± 9.04 52.54 ± 6.04 48.51 ± 10.38b 61.65 ± 3.60 51.70 ± 4.97b 58.86 ± 6.47 TNF-α 4.00 ± 0.69 4.73 ± 0.92* 3.87 ± 0.97 4.78 ± 0.80* 4.05 ± 1.09a,b 6.23 ± 1.01 4.26 ± 0.70a,b 6.91 ± 0.86 Note. C8:0, caprylic acid; C16:0, palmitic acid; EPA, eicosapentaenoic acid; HFD, high-fat diet; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor α; IL-1β, interleukin-1β; IL-6, interleukin-6; IL-10, interleukin-10; MCP-1, monocyte chemoattractant protein-1; *P < 0.05, versus LPS group; aP < 0.05, versus HFD group; bP < 0.05, versus C16:0 group; cP < 0.05, versus EPA group. Table 4. Effects of different fatty acids on the mRNA expression of ABCA1/JAK2/STAT3 pathway-related molecules in the aorta in C57BL/6j mice (
$\bar x$ ± s, n = 7)Indicators −LPS +LPS C8:0 C16:0 EPA HFD C8:0 C16:0 EPA HFD ABCA1 0.17 ± 0.04a,b,c,* 0.09 ± 0.02 0.11 ± 0.01* 0.09 ± 0.02 0.22 ± 0.02a,b,c 0.07 ± 0.03 0.14 ± 0.01b 0.10 ± 0.05 JAK2 0.21 ± 0.03b,* 0.14 ± 0.04* 0.18 ± 0.05 0.16 ± 0.04* 0.57 ± 0.23a,b,c 0.29 ± 0.15 0.17 ± 0.02 0.26 ± 0.10 STAT3 0.23 ± 0.05a,* 0.17 ± 0.06* 0.19 ± 0.03* 0.15 ± 0.03* 0.93 ± 0.30a,b,c 0.26 ± 0.05 0.34 ± 0.15 0.38 ± 0.16 TNF-α 0.08 ± 0.01a,b,* 0.15 ± 0.04* 0.08 ± 0.02a,b,* 0.17 ± 0.06* 0.15 ± 0.06a,b 0.27 ± 0.08 0.14 ± 0.06a,b 0.26 ± 0.07 NF-κB 0.08 ± 0.03a,b,* 0.13 ± 0.03* 0.09 ± 0.02a,b 0.15 ± 0.03* 0.12 ± 0.02a 0.18 ± 0.04 0.10 ± 0.04a 0.24 ± 0.08 Note. C8:0, caprylic acid; C16:0, palmitic acid; EPA, eicosapentaenoic acid; HFD, high-fat diet; LPS, lipopolysaccharide; ABCA1, ATP-binding cassette transporter A1; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; TNF-α, tumor necrosis factor α; NF-κB, nuclear factor kappa B; *P < 0.05, versus +LPS (comparison in the same group ±LPS); aP < 0.05, versus HFD group; bP < 0.05, versus C16:0 group;
cP < 0.05, versus EPA group. -
[1] Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American heart association. Circulation, 2017; 135, e146−603. [2] Dasu MR, Jialal I. Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors. Am J Physiol Endocrinol Metab, 2011; 300, E145−54. doi: 10.1152/ajpendo.00490.2010 [3] Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 2017; 376, 1713−22. doi: 10.1056/NEJMoa1615664 [4] Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA, 2016; 316, 1289−97. doi: 10.1001/jama.2016.13985 [5] Nguyen MTA, Favelyukis S, Nguyen AK, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem, 2007; 282, 35279−92. doi: 10.1074/jbc.M706762200 [6] Lee JY, Sohn KH, Rhee SH, et al. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem, 2001; 276, 16683−9. doi: 10.1074/jbc.M011695200 [7] Håversen L, Danielsson KN, Fogelstrand L, et al. Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. Atherosclerosis, 2009; 202, 382−93. doi: 10.1016/j.atherosclerosis.2008.05.033 [8] Nosaka N, Maki H, Suzuki Y, et al. Effects of margarine containing medium-chain triacylglycerols on body fat reduction in humans. J Atheroscler Thromb, 2003; 10, 290−8. doi: 10.5551/jat.10.290 [9] Zhang XS, Zhang Y, Liu YH, et al. Medium-chain triglycerides promote macrophage reverse cholesterol transport and improve atherosclerosis in ApoE-deficient mice fed a high-fat diet. Nutr Res, 2016; 36, 964−73. doi: 10.1016/j.nutres.2016.06.004 [10] Westerterp M, Murphy AJ, Wang M, et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res, 2013; 112, 1456−65. doi: 10.1161/CIRCRESAHA.113.301086 [11] Tang CR, Houston BA, Storey C, et al. Both STAT3 activation and cholesterol efflux contribute to the anti-inflammatory effect of apoA-I/ABCA1 interaction in macrophages. J Lipid Res, 2016; 57, 848−57. doi: 10.1194/jlr.M065797 [12] Tang CR, Liu YH, Kessler PS, et al. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem, 2009; 284, 32336−43. doi: 10.1074/jbc.M109.047472 [13] Zhang XS, Xue CY, Xu Q, et al. Caprylic acid suppresses inflammation via TLR4/NF-κB signaling and improves atherosclerosis in ApoE-deficient mice. Nutr Metab, 2019; 16, 40. doi: 10.1186/s12986-019-0359-2 [14] Liu YH, Zhang Y, Xu Q, et al. Increased norepinephrine by medium-chain triglyceride attributable to lipolysis in white and brown adipose tissue of C57BL/6J mice. Biosci Biotechnol Biochem, 2012; 76, 1213−8. doi: 10.1271/bbb.120079 [15] Hirotani Y, Fukamachi J, Ueyama R, et al. Effects of capsaicin coadministered with eicosapentaenoic acid on obesity-related dysregulation in high-fat-fed mice. Biol Pharm Bull, 2017; 40, 1581−5. doi: 10.1248/bpb.b17-00247 [16] Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis, 2017; 16, 149. doi: 10.1186/s12944-017-0541-3 [17] Vasandani C, Kafrouni AI, Caronna A, et al. Upregulation of hepatic LDL transport by n-3 fatty acids in LDL receptor knockout mice. J Lipid Res, 2002; 43, 772−84. doi: 10.1016/S0022-2275(20)30120-6 [18] Zhang Y, Xu Q, Liu YH, et al. Medium-chain triglyceride activated brown adipose tissue and induced reduction of fat mass in C57BL/6J mice fed high-fat diet. Biomed Environ Sci, 2015; 28, 97−104. [19] Zhang Y, Yang XY, Zhang XS, et al. Effects of medium-chain fatty acids on high-density-lipoprotein in rats fed with high fat diet. J Hyg Res, 2018; 47, 123−7. (In Chinese [20] Xu Q, Xue CY, Zhang Y, et al. Medium-chain fatty acids enhanced the excretion of fecal cholesterol and cholic acid in C57BL/6J mice fed a cholesterol-rich diet. Biosci Biotechnol Biochem, 2013; 77, 1390−6. doi: 10.1271/bbb.120999 [21] Abou-Saleh H, Ouhtit A, Halade GV, et al. Bone benefits of fish oil supplementation depend on its EPA and DHA content. Nutrients, 2019; 11, 2701. doi: 10.3390/nu11112701 [22] Daci A, Özen G, Uyar İ, et al. Omega-3 polyunsaturated fatty acids reduce vascular tone and inflammation in human saphenous vein. Prostaglandins Other Lipid Mediat, 2017; 133, 29−34. doi: 10.1016/j.prostaglandins.2017.08.007 [23] Papada E, Kaliora AC, Gioxari A, et al. Anti-inflammatory effect of elemental diets with different fat composition in experimental colitis. Br J Nutr, 2014; 111, 1213−20. doi: 10.1017/S0007114513003632 [24] Kono H, Fujii H, Asakawa M, et al. Medium-chain triglycerides enhance secretory IgA expression in rat intestine after administration of endotoxin. Am J Physiol Gastrointest Liver Physiol, 2004; 286, G1081−9. doi: 10.1152/ajpgi.00457.2003 [25] Babashamsi MM, Koukhaloo SZ, Halalkhor S, et al. ABCA1 and metabolic syndrome; a review of the ABCA1 role in HDL-VLDL production, insulin-glucose homeostasis, inflammation and obesity. Diabetes Metab Syndr, 2019; 13, 1529−34. doi: 10.1016/j.dsx.2019.03.004 [26] Basso F, Freeman L, Knapper CL, et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res, 2003; 44, 296−302. doi: 10.1194/jlr.M200414-JLR200 [27] Wellington CL, Brunham LR, Zhou S, et al. Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. J Lipid Res, 2003; 44, 1470−80. doi: 10.1194/jlr.M300110-JLR200 [28] Liu YH, Tang CR. Regulation of ABCA1 functions by signaling pathways. Biochim Biophys Acta, 2012; 1821, 522−9. doi: 10.1016/j.bbalip.2011.08.015 [29] Demina EP, Miroshnikova VV, Maĭorov NV, et al. ABCA1 mRNA and protein levels in M-CSF-activated macrophages from patients with arterial stenosis. Tsitologiia, 2013; 55, 580−5. [30] Zhang N, Han L, Xue YR, et al. The protective effect of magnesium lithospermate B on hepatic Ischemia/Reperfusion via inhibiting the Jak2/Stat3 signaling pathway. Front Pharmacol, 2019; 10, 620. doi: 10.3389/fphar.2019.00620 [31] Mason RP. New insights into mechanisms of action for Omega-3 fatty acids in atherothrombotic cardiovascular disease. Curr Atheroscler Rep, 2019; 21, 2. doi: 10.1007/s11883-019-0762-1 [32] Hao W, Wong OY, Liu XL, et al. ω-3 Fatty acids suppress inflammatory cytokine production by macrophages and hepatocytes. J Pediatr Surg, 2010; 45, 2412−8. doi: 10.1016/j.jpedsurg.2010.08.044 [33] Tanaka N, Irino Y, Shinohara M, et al. Eicosapentaenoic acid-enriched high-density lipoproteins exhibit anti-atherogenic properties. Circ J, 2018; 82, 596−601. doi: 10.1253/circj.CJ-17-0294 [34] Karasawa T, Takahashi M. Role of NLRP3 inflammasomes in atherosclerosis. J Atheroscler Thromb, 2017; 24, 443−51. doi: 10.5551/jat.RV17001 [35] Heo KN, Lin X, Han IK, et al. Medium-chain fatty acids but not L-carnitine accelerate the kinetics of [14C] triacylglycerol utilization by colostrum-deprived newborn pigs. J Nutr, 2002; 132, 1989−94. doi: 10.1093/jn/132.7.1989 -
21166Supplementary Materials.pdf